Programma overzicht

Coffee break

Tijd: 15:30 - 15:35 CET

✕

Drinks

Tijd: 17:00 - 17:05 CET

✕

Who can we spare immunotherapy? Biomarkers

Tijd: 16:30 - 16:35 CET

Prof. dr. Alessandra Curioni, University Freiburg, Germany

✕

Targeted treatment in early stage NSCLC

Tijd: 15:00 - 15:05 CET

No avatar

Dr. Suresh Ramalingan, Emory University, United States

✕

First line options for EGFR+ NSCLC

Tijd: 14:30 - 14:35 CET

No avatar

Prof. dr. David Planchard, Thoracic oncologist, Gustave Roussy

✕

Lunch

Tijd: 12:45 - 12:50 CET

✕

What to do with all these data?

Tijd: 10:40 - 10:45 CET

✕

Immunotherapy and comorbidities, the side effect treatment beyond steroids

Tijd: 16:00 - 16:05 CET

Prof. Jarushka Naidoo, Medical Oncologist, Beaumont Hospital And RCSI University

✕

Are you NUTs? Challenges and opportunities for the pathologist in tumors in the chest

Tijd: 12:00 - 12:05 CET

No avatar

Dr. Danielle Cohen, patholoog, LUMC

Dr. Gerrina Ruiter, Longarts, AVL

✕

Prevention of vaping. The facts and the struggle.

Tijd: 14:00 - 14:05 CET

No avatar

Frank Borm, Longarts, LUMC

✕

Coffee break

Tijd: 11:00 - 11:05 CET

✕

Surgery is key in the treatment of stage III NSCLC. 

Tijd: 10:20 - 10:25 CET

No avatar

Prof. Eric Lim, Brompton, London

✕

Radiotherapy is key in the treatment of stage III NSCLC

Tijd: 10:00 - 10:05 CET

No avatar

Matthias Guckenberger, University Hospital, Zurich

✕

Neo-adjuvant therapy: lessons from other malignancies (than NSCLC)

Tijd: 11:30 - 11:35 CET

Dr. Myrjam Chalabi, Internist-oncoloog, NKI-AVL

✕

The Legend of the RECIST criteria: Will Artificial Intelligence Take Over Tumor Measurement?

Tijd: 09:30 - 09:35 CET

No avatar

Illaa Smesseim, longarts en arts-onderzoeker, NKI-AVL

No avatar

Kevin Groot Lipman, NKI-AVL

✕

Welcome

Tijd: 09:00 - 09:05 CET

✕